trustme.bro/r/…
✓ checked
trust me, bro:
here is the receipt.
the claim
Hepatitis B vaccines for newborns are safe and cost-effective
the verdict
SUPPORTED
the evidence backs this
refutedsupported
the weight of evidence
5 sources for · 0 against

Evidence from global health data, systematic reviews, and economic models consistently supports the safety, efficacy, and cost-effectiveness of hepatitis B vaccination protocols for newborns and infants.

Evidence for · 5
Vertical transmission of hepatitis B virus: challenges and solutions
2014 · cited by 108
Demonstrates that at-birth hepatitis B vaccination for newborns of infected mothers is effective in preventing vertical transmission.
See more details
The analysis

The retrieved literature thoroughly supports the claim that hepatitis B vaccines are safe and cost-effective, particularly in the context of newborn and childhood immunization programs. Papers 1, 2, 4, 5, and 7 provide direct or supportive evidence regarding safety, efficacy, and cost-effectiveness (including modeling and review data). No papers refute the core claim.

More for · 4
Hepatitis B Vaccination: A Historical Overview with a Focus on the Italian Achievements
2022 · cited by 43
Shows that global infant and childhood hepatitis B vaccination programs have an excellent profile of safety, immunogenicity, and effectiveness.
Mathematical Model of Hepatitis B Disease with Optimal Control and Cost-Effectiveness Analysis
2023 · cited by 30
Indicates through mathematical modeling that enhanced newborn vaccination combined with prevention strategies is an effective and cost-saving approach.
Efficacy and safety of hepatitis B vaccine: an umbrella review of meta-analyses
2023 · cited by 25
Confirms through an umbrella review of meta-analyses that universal and targeted hepatitis B vaccination strategies are effective and safe.
Cost-effectiveness analysis of hepatitis B vaccine booster in children born to HBsAg-positive mothers in rural China.
2019 · cited by 14
Finds that specific booster strategies for high-risk children born to HBsAg-positive mothers are cost-effective.
Everything we examined (12)
We also searched for evidence AGAINST this claim, not only for it.
  1. Universal Hepatitis B Vaccination in Adults Aged 19–59 Years: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022peer-reviewedno side takennot shown: read and judged not to bear on this claim
  2. Vertical transmission of hepatitis B virus: challenges and solutionspeer-reviewedsupports
  3. Hepatitis B Vaccination: A Historical Overview with a Focus on the Italian Achievementspeer-reviewedsupports
  4. Efficacy and Safety of Hepatitis B Vaccination in Rheumatoid Arthritis Patients Receiving Disease-Modifying Antirheumatic Drugs and/or Biologics Therapypeer-reviewedno side takennot shown: read and judged not to bear on this claim
  5. Mathematical Model of Hepatitis B Disease with Optimal Control and Cost-Effectiveness Analysispeer-reviewedsupports
  6. Efficacy and safety of hepatitis B vaccine: an umbrella review of meta-analysespeer-reviewedsupports
  7. Systematic review of the efficacy and safety of intradermal versus intramuscular hepatitis B vaccination in end-stage renal disease population unresponsive to primary vaccination seriespeer-reviewedno side takennot shown: read and judged not to bear on this claim
  8. Cost-effectiveness analysis of hepatitis B vaccine booster in children born to HBsAg-positive mothers in rural China.peer-reviewedsupports
  9. Comparative cost-effectiveness of a 2-dose versus 3-dose vaccine for hepatitis B prevention in selected adult populations.peer-reviewedno side takennot shown: read and judged not to bear on this claim
  10. Early-stage hepatocellular carcinoma screening in patients with chronic hepatitis B in China: a cost–effectiveness analysispeer-reviewedno side takennot shown: read and judged not to bear on this claim
  11. Hepatitis B vaccine effectiveness among vaccinated children in Africa: a systematic review and meta-analysispeer-reviewedno side takennot shown: read and judged not to bear on this claim
  12. Cost-effectiveness of a 3-antigen versus single-antigen vaccine for the prevention of hepatitis B in adults in the United States.peer-reviewedno side takennot shown: read and judged not to bear on this claim
The paper trail · every fact has a biography
first checked06 Aug 2026
judged → SUPPORTED · 8806 Aug 2026
This receipt carries no identity, shared or not. Sharing publishes your connection to it, not your data.
Check your own claim
Challenge the receipt
trust me, bro: win the argument, pass the class, survive peer review.
This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work · Dispute this receipt